



August 21, 2018

✓ **BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of final USFDA approval for Hydrocortisone Butyrate Lotion, 0.1%, to market a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1%, which is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

For **R. V. SATAM**
COMPANY SECRETARY

Encl.: a.a.

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com



LUPIN

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin receives FDA approval for generic Hydrocortisone Butyrate Lotion, 0.1%

Mumbai, Baltimore, August 21, 2018: Pharma major Lupin announced that it has received final approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1%.

Lupin's Hydrocortisone Butyrate Lotion, 0.1% is the generic version of PreCision's Locoid Lotion, 0.1%. It is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.

Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximately USD 13.8million in the US (IQVIA MAT April 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.



LUPIN

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

For further information or queries, please contact –

Pooja Thakran

VP – Corporate Communications

Email: poojathakran@lupin.com

Ph: +91-22-66402531 / 8291013225

Neha Rao

Head - External Communications

Email: neharao@lupin.com

Ph: +91-22-66402409 / 9819073603

Arvind Bothra

Head – Investor Relations

Email: arvindbothra@lupin.com

Ph: +91-22-66402137

**Safe Harbor Statement*

Locoid Lotion is a registered trademark of Leo Pharma.